On February 10, 2025, President Donald Trump signed an executive order directing the U.S. attorney general, Pam Bondi, to pause Foreign Corrupt Practices Act (FCPA) actions for 180 days until she issues revised FCPA...more
2/13/2025
/ Anti-Corruption ,
Compliance ,
Corruption ,
Department of Justice (DOJ) ,
Enforcement Actions ,
Executive Orders ,
Foreign Corrupt Practices Act (FCPA) ,
Securities and Exchange Commission (SEC) ,
Trump Administration ,
Whistleblower Protection Policies ,
Whistleblowers ,
White Collar Crimes
The use of data analytics to identify potential violations of law has become increasingly sophisticated. Agencies like the Securities and Exchange Commission (SEC) have led the charge, employing risk-based data tools to...more
3/26/2024
/ Analytics ,
Artificial Intelligence ,
Compliance ,
Corporate Crimes ,
Data Privacy ,
Department of Justice (DOJ) ,
Government Investigations ,
Regulatory Agenda ,
Regulatory Requirements ,
Self-Reporting ,
Technology ,
Transparency ,
Whistleblowers ,
White Collar Crimes
On March 7, 2024, Deputy Attorney General (DAG) Lisa Monaco announced that the Department of Justice (DOJ) will soon launch a new monetary reward program for people who provide information about corporate or financial...more
A whistleblower has triggered a race against time: An internal inquiry, directed by the audit committee and overseen by external counsel, has been launched in response to allegations that revenue was recorded without proper...more
11/13/2023
/ Attorney-Client Privilege ,
Auditors ,
Confidential Information ,
Enforcement Actions ,
Financial Statements ,
Information Sharing ,
Internal Controls ,
Internal Investigations ,
Privilege Waivers ,
Securities and Exchange Commission (SEC) ,
Securities Litigation ,
Securities Regulation ,
Shareholders ,
Whistleblowers ,
Work-Product Doctrine
On March 15, 2018, Skadden hosted its Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar in Palo Alto, California, which focused on U.S. enforcement issues faced by companies throughout the industry. The...more
3/30/2018
/ Acquisitions ,
Anti-Kickback Statute ,
Biotechnology ,
Charitable Donations ,
Compliance ,
Corporate Integrity Agreement ,
Criminal Prosecution ,
Department of Justice (DOJ) ,
Donations ,
Drug Pricing ,
Enforcement Actions ,
False Claims Act (FCA) ,
First Amendment ,
Food and Drug Administration (FDA) ,
Gilead Sciences Inc v United States ex rel Campie ,
Health Care Providers ,
Health Insurance Portability and Accountability Act (HIPAA) ,
HIPAA Breach ,
Life Sciences ,
Materiality ,
Medical Devices ,
Medicare ,
Off-Label Promotion ,
OIG ,
Park Doctrine ,
Patient Assistance Programs ,
Petition for Writ of Certiorari ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Promotional Items ,
Split of Authority ,
Universal Health Services Inc v United States ex rel Escobar ,
Warning Letters ,
Whistleblowers